We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Recommends Bayer’s Xofigo With Restrictions
The National Institute for Health and Care Excellence has given the green light to Bayer’s Xofigo in England and Wales as an option for treating adults with hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases, albeit with restrictions.